ACTUALITES

SCIENTIFIC EVENTS

  • 2nd Symposium IRCI - 21st to 23rd of June, 2021, Lyon, France

2nd International Symposium on Immune Responses in Cancer and Infection (IRCI).
The event has been postponed to June, 2020 in Lyon, France.

IRCI is an international conference that occurs every three years with talks from experts in the field of immune responses in cancer and infection. This meeting is a unique chance for you to learn, exchange, and expose your results in a world class setting in which registration prices have been kept low.

More information on https://irci2021.insight-outside.fr/

SEMINARS

OTHER

LATEST PUBLICATIONS

  • Failed Apoptosis Enhances Melanoma Cancer CellAggressiveness

Triggering apoptosis remains an efficient strategy to treat cancer. However, apoptosis is no longer a final destination since cancer cells can undergo failed apoptosis without dying. Recent evidence shows that limited mitochondrial permeabilization and non-lethal caspase activation occur under certain circumstances, although it remains unclear how failed apoptosis affects cancer cells. Using an original cancer cell model to trigger non-lethal caspase activation, we find that melanoma cancer cells undergoing failed apoptosis have a particular transcriptomic signature associated with focal adhesions, transendothelial migration, and modifications of the actin cytoskeleton. In line with this, cancer cells surviving apoptosis gain migration and invasion properties in vitro and in vivo. We further demonstrate that failed apoptosis-associated gain in invasiveness is regulated by the c-Jun N-terminal kinase (JNK) pathway, whereas its RNA sequencing signature is found in metastatic melanoma. These findings advance our understanding of how cell death can both cure and promote cancer. 

  • Netrin-1 promotes naive pluripotency through Neo1 and Unc5b co-regulation of Wnt and MAPK signalling

In mouse embryonic stem cells (mESCs), chemical blockade of Gsk3α/β and Mek1/2 (2i) instructs a self-renewing ground state whose endogenous inducers are unknown. Here we show that the axon guidance cue Netrin-1 promotes naive pluripotency by triggering profound signalling, transcriptomic and epigenetic changes in mESCs. Furthermore, we demonstrate that Netrin-1 can substitute for blockade of Gsk3α/β and Mek1/2 to sustain self-renewal of mESCs in combination with leukaemia inhibitory factor and regulates the formation of the mouse pluripotent blastocyst. Mechanistically, we reveal how Netrin-1 and the balance of its receptors Neo1 and Unc5B co-regulate Wnt and MAPK pathways in both mouse and human ESCs. Netrin-1 induces Fak kinase to inactivate Gsk3α/β and stabilize β-catenin while increasing the phosphatase activity of a Ppp2r2c-containing Pp2a complex to reduce Erk1/2 activity. Collectively, this work identifies Netrin-1 as a regulator of pluripotency and reveals that it mediates different effects in mESCs depending on its receptor dosage, opening perspectives for balancing self-renewal and lineage commitment.

https://doi.org/10.1038/s41556-020-0483-2

JOB OPPORTUNITIES

  • May 2020 - PhD Position
IMPORTANT : you must apply online

PhD position at the CRCL, Lyon M/F "characterisation of the role of netrine-1 in the resistance and plasticity in humain colorectal cancers (P. Mehlen’s team)
https://emploi.cnrs.fr/Offres/Doctorant/UMR5286-BLABRU-003/Default.aspx?lang=EN

Ensure that your candidate profile is correct before applying. Your profile information will be added to the details for each application. In order to increase your visibility on our Careers Portal and allow employers to see your candidate profile, you can upload your CV to our CV library in one click!
  • March 2020 - Lab manager position

L’équipe « Régulation moléculaire de l’Immunité dans le Cancer » recherche un(e) candidat(e) motivé(e) pour un poste de Lab Manager (Technicien, Assistant Ingénieur ou Ingénieur d’Etudes).
Consulter l'offre

  • February 2020 - Post-doctoral position

A post-doctoral position is now available in the team of Dr. Gabriel Ichim. 
The main focus of the team is studying mitochondrial regulation of cell death and non-lethal caspase activation with a wide-range of implication in cancer cell invasiveness, resistance to therapy or cancer stem cells.
More information

  • January 2020 - Post-doctoral position

The laboratory of Dr. Julien C. Marie is seeking an experienced, creative and autonomous post-doctoral fellow to study the effects of TGF-B on T cell-biology.
More information

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :